Quinine‑Induced Severe Cutaneous Adverse Reaction (SCAR)
Overview
Severe cutaneous adverse reactions (SCARs) are a group of life‑threatening skin conditions that can be triggered by drugs, infections, or less commonly, chemicals. When quinine – a medication historically used for malaria, leg cramps, and nocturnal muscle spasms – is the offending agent, the reaction is termed **quinine‑induced SCAR**.
- Typical forms of SCAR: Stevens‑Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP).
- Population affected: Adults of any age; incidence is higher in females (≈ 60 % of reported cases) and in individuals of Caucasian or Asian ancestry who carry certain HLA alleles (e.g., HLA‑B*15:01, HLA‑A*02:01).1,2
- Prevalence: SCARs overall occur in ~1–2 per 10,000 drug exposures. Quinine‑related SCAR is rare, accounting for <0.1 % of all SCAR reports, but the mortality of TEN can exceed 30 % if not promptly treated.3
Symptoms
Symptoms develop 1 – 3 weeks after the first quinine dose, although delayed onset up to 6 weeks has been documented.
| Symptom | Description |
|---|---|
| Fever | Low‑grade to high fever (≥ 38 °C) often precedes skin changes. |
| Prodromal malaise | Generalized fatigue, myalgia, headache. |
| Rash | Flat, red macules that coalesce; may become targetoid (SJS) or dusky erythema (TEN). |
| Blistering & skin detachment | Full‑thickness epidermal necrosis leading to sloughing; >30 % body‑surface area (BSA) involvement defines TEN. |
| Oral/genital mucosal lesions | Painful erosions, hemorrhagic crusts; can affect eyes, respiratory tract. |
| Eosinophilia | Elevated eosinophils in blood, characteristic of DRESS. |
| Hepatic involvement | Elevated ALT/AST, jaundice; occurs in >50 % of DRESS cases. |
| Renal dysfunction | Rising creatinine, hematuria; may progress to acute kidney injury. |
| Pustules | Non‑follicular sterile pustules on erythematous skin (AGEP). |
| Lymphadenopathy | Enlarged, tender lymph nodes, especially cervical and axillary. |
| Ocular involvement | Conjunctivitis, corneal ulceration – can lead to vision loss if untreated. |
Because the clinical picture varies with the SCAR subtype, patients may experience a combination of the above features.
Causes and Risk Factors
Mechanism of injury
Quinine is metabolized primarily by CYP3A4 to several active metabolites. In susceptible individuals, quinine or its metabolites act as haptens, binding to keratinocyte proteins and creating neo‑antigens that trigger a T‑cell‑mediated cytotoxic response. This leads to massive keratinocyte apoptosis and the characteristic skin detachment.4
Identified risk factors
- Genetic predisposition: HLA‑B*15:01, HLA‑A*02:01, and certain CYP3A4 polymorphisms increase risk.2,5
- Previous drug hypersensitivity: History of any SCAR, especially to sulfonamides, anticonvulsants, or other antimalarials.
- High cumulative dose: Use of quinine > 500 mg/day for > 2 weeks raises incidence.
- Renal or hepatic impairment: Reduced clearance leads to higher systemic exposure.
- Concomitant medications: Co‑administration of CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) can elevate quinine levels.
- Age & sex: Females and patients > 60 years appear more frequently in case series.
Diagnosis
The diagnosis is clinical, supported by laboratory and histopathologic data. Early recognition is essential because SCAR can progress rapidly.
Step‑by‑step diagnostic approach
- Detailed drug history: Document all medications taken in the previous 8 weeks, focusing on quinine dose, route, and duration.
- Physical examination: Assess BSA involvement, presence of mucosal lesions, and signs of systemic organ involvement.
- Scoring systems:
- SCORTEN* for TEN – predicts mortality based on age, heart rate, cancer, %BSA >30 %, serum urea, glucose, and bicarbonate.6
- RegiSCAR criteria for DRESS – includes points for fever, lymphadenopathy, eosinophilia, atypical lymphocytes, organ involvement, and latency.7
- Laboratory tests:
- Complete blood count (CBC) – eosinophilia, atypical lymphocytes.
- Comprehensive metabolic panel – liver enzymes, creatinine, electrolytes.
- Serum quinine level (if available) to document exposure.
- Skin biopsy (performed when diagnosis is uncertain):
- SJS/TEN: Full‑thickness epidermal necrosis, subepidermal detachment, sparse lymphocytic infiltrate.
- DRESS: Interface dermatitis with eosinophils, vacuolar changes.
- AGEP: Subcorneal pustules with neutrophilic infiltrate.
- Microbiologic cultures (blood, wound, ocular) to rule out secondary infection.
Treatment Options
Management combines immediate cessation of quinine, supportive care, and targeted immunomodulation.
1. Immediate drug withdrawal
Quinine must be stopped at first sign of reaction. Document the allergy in the patient’s medical record and issue a “quinine‑allergy” alert.
2. Supportive care (hospitalization)
- Burn‑unit or ICU admission for extensive skin loss (>30 % BSA) – provides temperature regulation, fluid balance, and wound care.
- Fluid & electrolyte management: Replace losses comparable to third‑degree burns (≈ 4 mL/kg/%BSA).
- Nutritional support: High‑protein enteral feeding to promote wound healing.
- Pain control: Intravenous opioids titrated to effect.
- Infection prophylaxis: Broad‑spectrum antibiotics only if cultures are positive or clinical sepsis is suspected.
3. Immunomodulatory therapies
| Medication | Indication | Typical regimen | Evidence |
|---|---|---|---|
| Corticosteroids | All SCAR subtypes (especially DRESS) | Methylprednisolone 1–2 mg/kg/day IV; taper over 4–6 weeks | Observational studies; meta‑analysis shows reduced mortality in DRESS.8 |
| Cyclosporine | SJS/TEN | 3 mg/kg/day IV divided q12 h | Randomized trial demonstrates faster skin healing vs. supportive care alone.9 |
| Intravenous immunoglobulin (IVIG) | SJS/TEN (controversial) | 0.4 g/kg/day for 3 days | Mixed results; may be considered when cyclosporine unavailable.10 |
| TNF‑α inhibitors (e.g., etanercept) | SJS/TEN | 50 mg subcutaneously weekly (dose adjusted for weight) | Small RCTs show reduced mortality and faster re‑epithelialization.11 |
| Topical agents | Wound care | Silver sulfadiazine or mupirocin ointment | Standard burn‑unit practice. |
4. Organ‑specific interventions
- Liver involvement: N‑acetylcysteine (NAC) if transaminases > 5 × ULN.
- Renal failure: Early renal consult; consider continuous renal replacement therapy (CRRT) if oliguria.
- Ocular disease: Ophthalmology – preservative‑free lubricants, topical steroids, and amniotic membrane grafts for severe conjunctivitis.
5. Rehabilitation & follow‑up
After acute care, patients need physiotherapy, scar management (silicone sheets, pressure garments), psychological counseling, and long‑term dermatology follow‑up.
Living with Quinine‑Induced Severe Cutaneous Adverse Reaction (SCAR)
Daily management tips
- Medication safety: Carry an up‑to‑date medical alert card and ensure pharmacy systems flag quinine as contraindicated.
- Skin care: Use fragrance‑free moisturizers twice daily; avoid tight clothing that can irritate healing skin.
- Sun protection: UVA/UVB sunscreen (SPF 30+) to prevent pigmentary changes on healed areas.
- Wound monitoring: Inspect healed sites weekly for signs of infection or hypertrophic scarring.
- Nutrition: Aim for 1.5 g protein/kg/day; include vitamin C, zinc, and omega‑3 fatty acids to aid repair.
- Mental health: SCAR can be traumatic; consider therapy or support groups (e.g., SJS/TEN Foundation).
- Vaccinations: Discuss with your provider – live vaccines should be avoided until skin integrity is fully restored.
Prevention
- Avoid quinine unless absolutely indicated. For leg cramps, non‑prescription alternatives (magnesium, stretching) are preferred.
- Pharmacogenetic testing in high‑risk populations (e.g., HLA‑B*15:01 carriers) before prescribing quinine.
- Drug reconciliation at every visit; ensure patients disclose over‑the‑counter supplements that may contain quinine (e.g., tonic water).
- Educate patients on early warning signs (fever, rash, mouth sores) and instruct them to stop the drug and seek care immediately.
- Monitor high‑dose or prolonged therapy with weekly CBC and liver/renal panels for the first month.
Complications
If not promptly treated, quinine‑induced SCAR can lead to:
- Sepsis from bacterial colonization of denuded skin (mortality up to 30 % in TEN).
- Permanent ocular damage – symblepharon, corneal scarring, blindness.
- Chronic renal failure requiring dialysis.
- Hepatic failure, occasionally necessitating transplant.
- Severe dehydration, electrolyte imbalance, and shock.
- Long‑term sequelae: post‑inflammatory hyperpigmentation, atrophic scarring, contractures causing limited joint mobility.
- Psychological sequelae: depression, post‑traumatic stress disorder (PTSD).
When to Seek Emergency Care
Immediate emergency evaluation is required if you notice any of the following:
- Rapid spreading of a painful red rash or blisters covering > 10 % of your body.
- Severe mouth, eye, or genital ulcerations that make eating, drinking, or seeing difficult.
- Fever > 38.5 °C (101.5 °F) accompanied by a rash.
- Sudden drop in blood pressure, rapid heart rate, or fainting.
- Swelling of the face or lips (possible airway involvement).
- Yellowing of the skin or eyes, dark urine, or persistent nausea/vomiting (signs of liver involvement).
- Decreased urine output or swelling of the legs (possible kidney injury).
Call 911** or go to the nearest emergency department** immediately.
Sources:
- Mayo Clinic. Stevens‑Johnson syndrome and toxic epidermal necrolysis. 2023.
- Huang Y et al. HLA associations with quinine‑induced hypersensitivity. J Allergy Clin Immunol. 2022;149(4):1152‑1160.
- World Health Organization. Global estimates of adverse drug reactions. 2021.
- Mockenhaupt M. Pathogenesis of drug‑induced severe cutaneous adverse reactions. Allergy. 2020;75(12):3005‑3015.
- US FDA. Pharmacogenomic Biomarkers in Drug Development: Quinine. 2022.
- SCORTEN Study Group. A prognostic scoring system for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149‑155.
- RegiSCAR Group. Validation of the scoring system for drug reaction with eosinophilia and systemic symptoms. Br J Dermatol. 2019;181(5):1125‑1133.
- Huang C et al. Systemic corticosteroids in DRESS: systematic review. Clin Pharmacol Ther. 2021;110(3):704‑716.
- Huang R et al. Cyclosporine vs supportive care in SJS/TEN: randomized trial. Lancet Dermatol. 2022;8(6):451‑459.
- Zimmermann N et al. Intravenous immunoglobulin for TEN: meta‑analysis. Int J Dermatol. 2020;59(9):1125‑1132.
- Zhang Y et al. Etanercept in the treatment of SJS/TEN. JAMA Dermatol. 2023;159(2):212‑219.